JNJ vs MELI: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and MercadoLibre, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
VS
MercadoLibre, Inc. · Consumer Cyclical
$1,635.15
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
MELI has more upside to fair value
(+45.0%).
JNJ trades at a lower forward P/E
(29.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
MELI |
| Current Price |
$253.85 |
$1,635.15 |
| Fair Value Estimate |
$198.76 |
$2,370.97 |
| Upside to Fair Value |
-21.7%
|
+45.0%
|
| Market Cap |
$611.1B |
$82.9B |
| Forward P/E |
29.3x
|
43.2x
|
| EV / EBITDA |
19.2x
|
27.0x
|
| Price / Sales |
6.3x
|
2.6x
|
| Price / FCF |
34.3x
|
7.7x
|
| Revenue Growth YoY |
+9.9%
|
+49.0%
|
| Gross Margin |
69.1%
|
43.9%
|
| Operating Margin |
26.9%
|
9.6%
|
| Return on Equity |
26.3%
|
29.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.91%
|
12.92%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
MercadoLibre is a leading Latin American e-commerce and fintech platform with a durable competitive moat driven by its integrated logistics and financial services stack. The company commands approximately 30 to 35 percent market share in e-commerce and over 30 percent in online payments in key markets like Brazil. It is founder-influenced with a long-tenured management team and reinvests heavily …
Accumulation Zones
| Metric |
JNJ |
MELI |
| Zone Low |
$149.07 |
$1,778.23 |
| Zone High |
$168.95 |
$2,015.32 |
| In Buy Zone? |
No
|
Yes
|